Generali (XTER:ASG) Research & Development: €0 Mil (TTM As of Dec. 2025)


XTER:ASG Generali XTER:ASG
56 GF Score
Price €42.54
GF Value €38.47
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Generali Research & Development?

Generali XTER:ASG +0.19% 56 Research & Development is €0 Mil as of Dec. 2025. GuruFocus rates XTER:ASG with a GF Score™ of 56/100 and a GF Value™ of €38.47 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Generali's Research & Development for the three months ended in Dec. 2025 was €0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0 Mil.

Generali  (XTER:ASG) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Generali Research & Development Related Terms

Generali Research & Development Historical Data

* Premium members only.

The historical data trend for Generali's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generali Research & Development Chart

Generali Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Generali Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XTER:ASG
56GF Score
Generali XTER:ASG
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Generali Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0 Mil mean?
Generali (XTER:ASG) has a Research & Development of €0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Generali and its competitors.
Is Generali's Research & Development too high?
Generali's current Research & Development is €0 Mil. Overall, Generali has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Generali's Research & Development compare to BRK.A and AIG?
Generali's Research & Development of €0 Mil can be compared against companies in the Insurance industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Insurance company?
A good Research & Development depends on the Insurance industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Generali and its competitors. Generali's current Research & Development is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generali stock overvalued right now?
Based on GuruFocus' analysis, Generali (XTER:ASG) is currently considered Modestly Overvalued. The stock's GF Value™ is €38.47, compared to a current price of €42.54 — trading 10.6% above its estimated fair value. The current Research & Development is €0 Mil. Generali's overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Generali (XTER:ASG), the current Research & Development is €0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Generali (XTER:ASG) Overvalued in 2026?

Based on GuruFocus' analysis, Generali stock appears to be overvalued. The current stock price of €42.54 is trading 10.6% above its estimated GF Value™ of €38.47. GuruFocus considers Generali to be Modestly Overvalued.

Key valuation signals for XTER:ASG:

  • Research & Development: €0 Mil
  • GF Value™: €38.47 vs. price of €42.54 (10.6% above fair value)
  • GF Score™: 56/100 with 1 warning sign

No single metric tells the full story. See the XTER:ASG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Generali Business Description

Address Piazza Duca degli Abruzzi, 2, Trieste, ITA, 34132
The roots of Generali date back to the 1830s and the Bora wind and rough seas that hit the Trieste region. Over that decade, Generali sought to expand throughout Italy, but growth was held back by the fragmented nature of Italy. The Italian Revolution in the 1840s paved the way for easier expansion in the country. After World War I, Trieste was handed back to Italy. The dissolution of the Austro-Hungarian Empire created a fragmented Europe and a fragmented Generali. To this day, Generali remains quite a diversified company, with its core operations remaining in the historical Austro-Hungarian countries of Austria, Central and Eastern Europe, Germany, and Italy. France is also an important contributor to life and savings.
56GF Score

Get the complete analysis for XTER:ASG

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€42.54
Price
€38.47
GF Value